Howard Wenocur, MD
Internal Medicine · Philadelphia, PANPI 1063457596
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,525 of the $3,748 with a category attached, or 67.4%. 24 manufacturers reported payments, led by Novo Nordisk AS at 47.2% of the total. Reporting peaked in 2019 at $2,446 and has fallen 98.6% since, to $34 in 2023.
Across 126 payments — averaging $29.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- Novo Nordisk$244
- Amarin Pharma, Inc.$208
- AbbVie$202
- Amgen$191
- AstraZeneca$165
- plus $968 from 18 others
Across 689 payments — averaging $788.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$506K
- AstraZeneca$19K
- GRT US Holding, Inc.$19K
- Novo Nordisk$48
What the payments were for
- Travel & lodging$1,22333%
- Food & beverage$2,52567%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,771 |
| Novo Nordisk | 14 | $244 |
| Amarin Pharma, Inc. | 14 | $208 |
| AbbVie(2 entities) | 13 | $202 |
| Amgen | 10 | $191 |
| AstraZeneca | 12 | $165 |
| Pfizer | 10 | $147 |
| Lilly USA, LLC | 8 | $134 |
| Johnson & Johnson(2 entities) | 7 | $128 |
| Astellas Pharma US Inc | 5 | $77 |
| GSK | 4 | $61 |
| Merck | 4 | $60 |
| Boehringer Ingelheim | 4 | $60 |
| Orexo US, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Gilead | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Kaleo, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
How this compares
$3,748 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 14 | $175 |
| Metoprolol Succinate | 25 | $168 |
| Lorazepam | 16 | $139 |
| Pantoprazole Sodium | 12 | $85 |
| Amlodipine Besylate | 21 | $80 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.